Clinical Trials Directory

We are doing this study to find out if adding drugs that target HER2 proteins to the standard therapy for endometrial cancer can improve the chance of remission or lower the risk that the cancer comes back after treatment. We want to know how well patients do on the standard treatment compared to two experimental study regimens.

To join this study, patients must have bladder cancer proven by a lab test. The cancer must be in stages called cT2 to T3 and must not have spread to the lymph nodes or other parts of the body. Before joining, patients need a surgery called TURBT to remove as much of the tumor as possible. Patients also need scans of the chest, belly, and pelvis using CT or MRI to make sure the cancer has not spread. If any lymph nodes look big, they must be tested to show there is no cancer. Patients cannot have cancer that has spread or certain types of bladder cancer. Patients must be 18 or older. They cannot have had radiation to the pelvis before. If they had other treatments, any side effects must be mostly gone.

We are doing this study to find out if an experimental drug called cemiplimab (the study drug) is a safe and effective option for people who have untreated cutaneous squamous cell carcinoma (CSCC). We want to know if the study drug can help shrink this cancer and prevent it from returning after it is treated with surgery.

We are doing this study to find out if stereotactic body radiation therapy (SBRT) might be beneficial for people with non-small cell lung cancer (NSCLC). We want to compare the outcomes between the standard treatment for NSCLC and the standard treatment with the addition of SBRT.

We are doing this study to find out if an experimental drug called NT-101 (the study drug) is a safe and effective option for people with wet age-related macular degeneration (AMD). The study drug is a topical solution that is administered directly to the eye (eye drops).

We are doing this study to find the most effective, safe dose of an experimental drug called NX-5948 (the study drug). We want to know how well this study drug works in people with B-cell lymphomas.

We are doing this study to find out if an experimental drug called DefenCath® (the study drug) is a safe and effective means to lower the risk of central line infections for people who need total parenteral nutrition (TPN). TPN is when people get their necessary nutrients through a catheter in a vein because they are unable to properly digest food for nutrition. We want to know how well the study drug works compared to heparin catheter lock solution, which is the current option to help prevent infections.

We are doing this study to find the most effective, safe dose of an experimental drug called NVL-655 (the study drug). We want to know how well the study drug works compared to alectinib, which is a standard treatment for NSCLC.